Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer
Drug Development Research · 2025-09 · 86 (6)
DOI: 10.1002/ddr.70153 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 08.09.2025. Verfasst von Chandrakant S Gawli und 5 weiteren Autor:innen. Beteiligte Einrichtung: R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Acrylamides, Lung Neoplasms, Aniline Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: The authors would like to thank the Indian Council of Medical Research (ICMR) for funding the Investigator Initiated Research Projects-Intermediate Extramural….
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer‐related mortality, with “epidermal growth factor receptor (EGFR)” mutations playing a pivotal role in tumor progression and carcinogenesis. “Third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs),” such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives. Lazertinib, a structurally optimized third‐generation EGFR‐TKI, exhibits superior selectivity for mutant EGFR while sparing wild‐type EGFR, thereby reducing off‐target toxicities. This current opinion highlights the pharmacological properties of Lazertinib, its enhanced binding interactions, and its efficacy in overcoming resistance while demonstrating an improved safety profile. Comparative analyses reveal that Lazertinib offers stronger inhibition of key EGFR mutations, superior pharmacokinetics, and lower cardiotoxicity risks compared to Osimertinib. Additionally, Lazertinib's improved central nervous system (CNS) penetration enhances its therapeutic potential in patients with brain metastases. As ongoing clinical trials further elucidate its role, Lazertinib emerges as a promising next‐generation EGFR inhibitor, offering a safer and more effective alternative for NSCLC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
- Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
ORCID-Profile: Chandrakant S Gawli, Narendra R Nagpure, Bhatu R Patil, Nobuaki Ochi, Nagio Takigawa, Harun M Patel
Förderung
- The authors would like to thank the Indian Council of Medical Research (ICMR) for funding the Investigator Initiated Research Projects-Intermediate Extramural…
Zitieren
APA
Gawli, C. S., Nagpure, N. R., Patil, B. R., Ochi, N., Takigawa, N., & Patel, H. M. (2025). Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer. Drug Development Research, 86(6). https://doi.org/10.1002/ddr.70153
Vancouver
Gawli CS, Nagpure NR, Patil BR, Ochi N, Takigawa N, Patel HM. Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer. Drug Development Research. 2025;86(6). doi:10.1002/ddr.70153
BibTeX
@article{Gawli2025,
author = {Gawli, Chandrakant S and Nagpure, Narendra R and Patil, Bhatu R and Ochi, Nobuaki and Takigawa, Nagio and Patel, Harun M},
title = {Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer},
journal = {Drug Development Research},
year = {2025},
volume = {86},
number = {6},
doi = {10.1002/ddr.70153}
}
EUVIMED